AMPH
Amphastar Pharmaceuticals, Inc.
25.40$
+0.3%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -62.9% | +131.7% | +25.0% | -13.2% | -51.6% | +20.9% | +1.5% | +47.7% | -37.5% | +45.6% | +7.3% | – | |
| – | +1.6% | +1.3% | +1.3% | -129.0% | – | +3.7% | -14.4% | +8.5% | +13.2% | -10.3% | +29.7% | – | |
| – | -0.5% | +59.2% | -21.5% | -3.2% | +0.6% | +49.0% | -24.0% | -1.3% | -1.5% | +49.5% | -23.5% | – | |
| – | – | – | – | -184.9% | – | – | – | – | -456.2% | – | -116.9% | – | |
| – | -7.4% | -6.9% | -31.3% | +128.2% | -10.0% | -13.8% | -1.2% | -49.4% | +54.7% | +14.9% | -9.6% | – | |
| – | +230.8% | – | -558.8% | -50.5% | +3.2% | – | -106.0% | +3,039.0% | +208.7% | -72.4% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -129.8% | -50.9% | +311.4% | +20.1% | -73.8% | +256.5% | – | -140.9% | +43.8% | +53.3% | – | |
| – | – | – | – | – | -49.8% | -66.3% | +155.1% | -96.9% | +32.0% | -117.2% | +1,710.3% | – | |
| – | -154.4% | -71.2% | -21.1% | +112.9% | +48.3% | -57.1% | +108.2% | -85.6% | +322.7% | +64.4% | +44.1% | – | |
| – | -205.6% | – | -120.3% | – | -1,722.2% | – | -84.3% | +482.4% | -261.3% | – | +6,812.7% | – | |
| – | -73.4% | +222.4% | +35.6% | -26.8% | -64.0% | +46.8% | +2.7% | +88.7% | -47.9% | +55.9% | +11.5% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.